About: A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 29 April 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 2007 (uk) article scientifique publié en 2007 (fr) scientific article published on 29 April 2007 (en) artículu científicu espublizáu n'abril de 2007 (ast)
publication date	wds:Q80241635-B2A11392-B0F9-4870-863E-25D8A34111CF
publication date	2007-04-29 00:00:00Z (xsd:dateTime)
author name string	wds:Q80241635-002BDDBE-6BF7-4B62-BCE3-BC5DE3677D2F wds:Q80241635-069F893F-CF3B-4718-B467-66EAADCF000D wds:Q80241635-0AA0C2AD-3AA3-41EC-ABE1-EAC599F627E1 wds:Q80241635-149BED28-0E3C-49DA-9F50-145BDF1B3EE4 wds:Q80241635-156AD187-A8BC-45BB-BFFF-CCCE0820C2D4 wds:Q80241635-307BF86F-FB2A-484C-A4B1-5CC0B3691351 wds:Q80241635-40DC3548-B9AB-4177-B719-1A57FDB14037 wds:Q80241635-4F052934-5749-4955-BE9A-10E5262C5EC4 wds:Q80241635-80548C96-EDA4-48CF-9BB5-8A16167C9675 wds:Q80241635-92C6DAE4-0698-417C-8E00-58262748CE2D wds:Q80241635-C11E0C86-A873-4A8D-ADEF-8640C1FF6D26 wds:Q80241635-EA17301F-9F24-4F02-AE7D-2516C1BBF926 wds:Q80241635-FDE5E581-A871-457F-8F3C-0D1B59AE4A55
author name string	J Moore T Miller A Molina A Younes D Fisher J P Leonard B McKinney M Czuczman A Forero-Torres J W Friedberg D Finucane P Stiff N Chieffo
rdfs:label	A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma (en) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma (nl)
skos:prefLabel	A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma (en) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma (nl)
name	A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma (en) A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma (nl)
author	wds:Q80241635-A5C113E9-7FE0-4B0E-9555-B7732EBD4274 wds:Q80241635-F2CDD2AF-5DF0-4692-B5B6-72AFCC2DD2EE
author	Bruce D. Cheson Leo Gordon
title	wds:Q80241635-763437C3-10F6-4B02-BBF7-55B1092EA202
title	A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma (en)
page(s)	wds:Q80241635-B7E3759C-3091-4935-BF1A-FC11AEAEFB6B
page(s)	1216-1223
instance of	wds:Q80241635-9089624B-D285-48DC-80D9-A34AB154591D
instance of	scholarly article
main subject	wds:Q80241635-054BB576-B392-4798-BD6D-E66B6F68AA9D wds:Q80241635-B757BDEE-A0A1-414F-97AD-FFD408FEB037 wds:Q80241635-E8419D97-A7EF-4F85-95F6-FF09CAFF61E7
main subject	follicular lymphoma monoclonal antibody rituximab
PubMed ID	wds:Q80241635-914B8B15-C72E-4E69-9098-50662CF4E9F1
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17470451
PubMed ID	17470451
published in	wds:Q80241635-502801AD-2236-44E5-B21C-A080E6FB4862
published in	Annals of Oncology
issue	wds:Q80241635-38E3725E-4C36-4495-AC8B-DC01BF02DAAE
volume	wds:Q80241635-18717948-2730-4CC8-A6CE-C6C21463B162
issue	7
volume	18
DOI	wds:Q80241635-E6B338DF-93FD-47B2-9308-A413A4276BBD
DOI	http://dx.doi.org/10.1093/ANNONC/MDM114
DOI	10.1093/ANNONC/MDM114
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q80241635
is cites work of	Follicular lymphoma: 2012 update on diagnosis and management Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Follicular lymphoma: 2011 update on diagnosis and management Novel Drugs in Follicular Lymphoma Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Emerging antibody combinations in oncology Immunotherapy of cancer Use of antibodies and immunoconjugates for the therapy of more accessible cancers Non-Hodgkin's lymphoma in the elderly The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma Cancer-associated myeloproliferation: old association, new therapeutic target Novel agents for B-cell non-Hodgkin lymphoma: science and the promise Novel agents in indolent lymphomas. The role of B7 family molecules in hematologic malignancy The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Manipulation of costimulatory molecules by intracellular pathogens: veni, vidi, vici!! Current and emerging treatments for chronic lymphocytic leukaemia Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster Antibodies to watch in 2010 Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma Recent advances in the treatment of follicular lymphoma. Rapid Generation of Human-Like Neutralizing Monoclonal Antibodies in Urgent Preparedness for Influenza Pandemics and Virulent Infectious Diseases Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives Targeted treatment and new agents in follicular lymphoma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software